Tetraphase Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Tetraphase Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
1,294,615
2.45%
0
0%
07/31/2018
iShares Russell 2000 ETF
1,138,470
2.15%
-609
0.01%
09/06/2018
Vanguard Extended Market Index Fund
721,586
1.37%
0
0%
07/31/2018
iShares Nasdaq Biotechnology ETF
590,356
1.12%
-7,728
0.02%
09/06/2018
Tekla Healthcare Investors
574,944
1.09%
0
0.19%
12/31/2017
DFA US Small Cap Portfolio
573,416
1.09%
45,532
0.01%
04/30/2018
iShares Russell 2000 Value ETF
459,931
0.87%
0
0.02%
09/06/2018
Candriam Equities L - Biotechnology
370,000
0.7%
-135,000
0.1%
07/31/2018
DFA US Targeted Value Portfolio
295,059
0.56%
295,059
0.01%
04/30/2018
Tekla Life Sciences Investors
284,378
0.54%
0
0.21%
12/31/2017
| Address |
480 Arsenal Street
Watertown Massachusetts 02472
United States
|
|
Employees
|
- |
| Website |
http://www.tphase.com |
| Updated |
07/08/2019 |
| Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA. |
